Press Release: Filing of an amendment to the French "Document d'Enregistrement Universel" containing the Annual Financial Report

On March 4, 2026, Sanofi announced the filing of an amendment to its "Document d'Enregistrement Universel" that includes the Annual Financial Report with the French financial market regulator Autorité des marchés financiers (AMF). This amendment specifically introduces enhancements to the corporate governance report, in compliance with French regulations. Interested parties can access the updated document on Sanofi's official website as well as the AMF's site.

Sanofi, a research-driven and AI-powered biopharmaceutical company, is committed to enhancing the quality of lives through innovative treatments and vaccines. The company leverages its extensive understanding of the immune system to develop medicines that protect and benefit millions globally. With a strong emphasis on innovation, Sanofi’s pipeline aims to address pressing healthcare challenges and improve societal health outcomes. The firm prioritizes not only the advancement of science but also the creation of meaningful impacts on communities, focusing on urgent healthcare, environmental, and social issues.

For further inquiries, Sanofi has provided contact details for media relations and investor relations, offering a means for stakeholders to engage with the company on its latest developments and commitments.

Sanofi is publicly traded on both EURONEXT under the symbol SAN and NASDAQ as SNY, demonstrating its robust presence in the financial markets. The company's ongoing efforts reflect its dedication to science and social responsibility as it navigates the complexities of the biopharmaceutical industry.

Sanofi’s recent release regarding the amendment to its “Document d’Enregistrement Universel,” which includes the Annual Financial Report filings, offers critical insights for investors contemplating their next moves in the biopharma sector. The filing, while standard regulatory compliance, emphasizes enhancements in corporate governance—a key metric that can bolster investor confidence.

Sanofi's commitment to R&D, underscored by its focus on leveraging artificial intelligence to drive innovation, positions it favorably amid an increasingly competitive landscape. The mention of an innovative pipeline indicates potential for growth and profitability as new therapies may soon be introduced into the market to address unmet medical needs.

Investors should closely monitor the specifics of the annual financial report once published in full. Key performance indicators such as revenue growth, profit margins, and R&D expenditure will be essential to gauge the company’s operational health and its capacity for sustainable growth. Furthermore, improvements in corporate governance practices are likely to attract institutional investment, leading to increased stock stability long-term.

Given that Sanofi is listed on both Euronext and NASDAQ, the stock presents opportunities for diversified investment strategies. The dual listing also offers a chance for investors to benefit from currency fluctuations between the Euro and US Dollar, an additional layer of strategic consideration.

As the healthcare sector continues to evolve—particularly in areas influenced by technology and regulatory shifts—investors should remain vigilant. It’s advisable to review Sanofi’s quarterly results following this amendment closely, keeping an eye on market reactions post-release, which could lead to advantageous entry points or shifts in risk appetite.

In summary, the filing reinforces Sanofi’s strategic direction, and its commitment to improving governance and innovation makes it a contender worth monitoring for both short-term trading and long-term investment strategies.